| Year |
Citation |
Score |
| 2024 |
Jiang JJ, Chen C, Nian L, Liu Y, Ma J, Wang CY, Li ZY. [Effects of and Knockout on Ferroptosis Sensitivity of RPMI-8226 Cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 32: 1444-1449. PMID 39479830 DOI: 10.19746/j.cnki.issn.1009-2137.2024.05.022 |
0.342 |
|
| 2024 |
Liu JQ, Jabbari A, Lin CH, Akkanapally V, Frankel WL, Basu S, He K, Zheng P, Liu Y, Bai XF. IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10. Journal of Immunology (Baltimore, Md. : 1950). PMID 38975727 DOI: 10.4049/jimmunol.2400056 |
0.446 |
|
| 2024 |
Ahodantin J, Wu J, Funaki M, Flores J, Wang X, Zheng P, Liu Y, Su L. Siglec-H plasmacytoid dendritic cells protects against acute liver injury by suppressing IFN-γ/Th1 response and promoting IL-21 CD4 T cells. Cellular and Molecular Gastroenterology and Hepatology. 101367. PMID 38849082 DOI: 10.1016/j.jcmgh.2024.101367 |
0.475 |
|
| 2023 |
Muthana MM, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. Elife. 12. PMID 38127423 DOI: 10.7554/eLife.87281 |
0.526 |
|
| 2023 |
Bailey C, Wei Y, Yan J, Huang D, Zhang P, Qi C, Lazarski C, Su J, Tang F, Wong CS, Zheng P, Liu Y, Liu Y, Wang Y. Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease. Cell Reports. Medicine. 101236. PMID 37827154 DOI: 10.1016/j.xcrm.2023.101236 |
0.474 |
|
| 2023 |
Magenau JM, Jaglowski SM, Uberti J, Farag SS, Mansour Riwes M, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun TM, Devenport M, Lu S, Banerjee B, DaSilva C, Devine SM, ... ... Liu Y, et al. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease. Blood. PMID 37647633 DOI: 10.1182/blood.2023020250 |
0.433 |
|
| 2023 |
Wu X, Srinivasan P, Basu M, Zimmerman T, Li S, Wang Y, Zheng P, Liu Y, Sandler AD. CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma. Frontiers in Immunology. 14: 1176370. PMID 37346042 DOI: 10.3389/fimmu.2023.1176370 |
0.509 |
|
| 2023 |
Wu H, Ding P, Wu J, Sun C, Guo H, Chen S, Lowe S, Yang P, Tian Y, Liu Y, Zhao Q. A New Online Dynamic Nomogram: Construction and Validation of a Predictive Model for Distant Metastasis Risk and Prognosis in Patients with Gastrointestinal Stromal Tumors. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 37231240 DOI: 10.1007/s11605-023-05706-9 |
0.391 |
|
| 2023 |
Liu Y, Zheng P. CD24-Siglec interactions in inflammatory diseases. Frontiers in Immunology. 14: 1174789. PMID 37228622 DOI: 10.3389/fimmu.2023.1174789 |
0.472 |
|
| 2023 |
Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, Jiang J, Wu Q, Qiao J, Chen W, Cao J, Yan Z, Shi M, Cheng H, Zhu F, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Frontiers in Immunology. 14: 1169071. PMID 37153543 DOI: 10.3389/fimmu.2023.1169071 |
0.366 |
|
| 2023 |
Muthana MM, Du X, Liu M, Wang X, Wu W, Ai C, Su L, Zheng P, Liu Y. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. Biorxiv : the Preprint Server For Biology. PMID 36909522 DOI: 10.1101/2023.03.01.530608 |
0.526 |
|
| 2023 |
Liu M, Wang X, Du X, Wu W, Zhang Y, Zhang P, Ai C, Devenport M, Su J, Muthana MM, Su L, Liu Y, Zheng P. Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Science Translational Medicine. 15: eabm5663. PMID 36857433 DOI: 10.1126/scitranslmed.abm5663 |
0.516 |
|
| 2023 |
Ding P, Wu J, Wu H, Sun C, Guo H, Lowe S, Yang P, Tian Y, Liu Y, Meng L, Zhao Q. Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib. Bmc Gastroenterology. 23: 23. PMID 36690935 DOI: 10.1186/s12876-023-02658-x |
0.381 |
|
| 2022 |
Tanno T, Zhang P, Bailey C, Wang Y, Ittiprasert W, Devenport M, Zheng P, Liu Y. A novel aptamer-based small RNA delivery platform and its application to cancer therapy. Genes & Diseases. 10: 1075-1089. PMID 37396505 DOI: 10.1016/j.gendis.2022.05.004 |
0.451 |
|
| 2022 |
Zhou Y, Shen H, Wu M, Wang J, Wu Z, Fu F, Liu Y, Lu J, Yao Y, Luo N, Zhou S, Tan KS, Chen B, Wang D. Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy. International Journal of Biological Macromolecules. 229: 158-167. PMID 36587633 DOI: 10.1016/j.ijbiomac.2022.12.258 |
0.302 |
|
| 2022 |
Ding P, Yang P, Yang L, Sun C, Chen S, Li M, Lowe S, Guo H, Tian Y, Liu Y, Zhao Q. Impact of skeletal muscle loss during conversion therapy on clinical outcomes in lavage cytology positive patients with gastric cancer. Frontiers in Oncology. 12: 949511. PMID 36313681 DOI: 10.3389/fonc.2022.949511 |
0.374 |
|
| 2022 |
Guo H, Ding P, Sun C, Yang P, Tian Y, Liu Y, Lowe S, Bentley R, Li Y, Zhang Z, Wang D, Li Y, Zhao Q. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. Frontiers in Oncology. 12: 927781. PMID 36091139 DOI: 10.3389/fonc.2022.927781 |
0.399 |
|
| 2022 |
Ding P, Guo H, He X, Sun C, Lowe S, Bentley R, Zhou Q, Yang P, Tian Y, Liu Y, Yang L, Zhao Q. Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST. Bmc Gastroenterology. 22: 399. PMID 36028812 DOI: 10.1186/s12876-022-02479-4 |
0.373 |
|
| 2022 |
Wang X, Liu M, Zhang J, Brown NK, Zhang P, Zhang Y, Liu H, Du X, Wu W, Devenport M, Tao W, Mao-Draayer Y, Chen GY, Chen YE, Zheng P, ... Liu Y, et al. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder. Cell Metabolism. 34: 1088-1103.e6. PMID 35921817 DOI: 10.1016/j.cmet.2022.07.005 |
0.457 |
|
| 2022 |
Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S, Li T, Devenport M, Liu Y, Zheng P. CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. Signal Transduction and Targeted Therapy. 7: 224. PMID 35835736 DOI: 10.1038/s41392-022-01030-x |
0.479 |
|
| 2022 |
Welker J, Pulido JD, Catanzaro AT, Malvestutto CD, Li Z, Cohen JB, Whitman ED, Byrne D, Giddings OK, Lake JE, Chua JV, Li E, Chen J, Zhou X, He K, ... ... Liu Y, et al. Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Infectious Diseases. PMID 35286843 DOI: 10.1016/S1473-3099(22)00058-5 |
0.398 |
|
| 2022 |
Bailey CM, Liu Y, Liu M, Du X, Devenport M, Zheng P, Liu Y, Wang Y. Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. The Journal of Clinical Investigation. PMID 35239514 DOI: 10.1172/JCI150846 |
0.468 |
|
| 2022 |
Liu Y, Nelson MV, Bailey C, Zhang P, Zheng P, Dome JS, Liu Y, Wang Y. Correction: Targeting the HIF-1α-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor. Oncogene. PMID 35046533 DOI: 10.1038/s41388-021-02042-7 |
0.447 |
|
| 2022 |
Song NJ, Allen C, Vilgelm AE, Riesenberg BP, Weller KP, Reynolds K, Chakravarthy KB, Kumar A, Khatiwada A, Sun Z, Ma A, Chang Y, Yusuf M, Li A, Zeng C, ... ... Liu Y, et al. Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. Journal of Hematology & Oncology. 15: 5. PMID 35012610 DOI: 10.1186/s13045-021-01222-y |
0.481 |
|
| 2021 |
Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MWY, Liu JQ, Love R, Liu CG, Godfrey V, Shen R, ... ... Liu Y, et al. FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene. Cell. 184: 6378. PMID 34942100 DOI: 10.1016/j.cell.2021.11.030 |
0.423 |
|
| 2021 |
Liu Y, Chen W, Yu M, Li H, Cheng H, Cao J, Yan Z, Shi M, Zhu F, Sun H, Sang W, Li D, Wu Q, Chen C, Zheng J, et al. Absolute lymphocyte count prior lymphodepletion impacts outcomes in multiple myeloma patients treated with CAR-T cells. Transplantation and Cellular Therapy. PMID 34861455 DOI: 10.1016/j.jtct.2021.11.016 |
0.356 |
|
| 2021 |
Zhu JY, Huang X, Fu Y, Wang Y, Zheng P, Liu Y, Han Z. Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes. Disease Models & Mechanisms. PMID 34580712 DOI: 10.1242/dmm.048953 |
0.46 |
|
| 2021 |
Peng G, Wang Y, Ge P, Bailey C, Zhang P, Zhang D, Meng Z, Qi C, Chen Q, Chen J, Niu J, Zheng P, Liu Y, Liu Y. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin. Journal of Experimental & Clinical Cancer Research : Cr. 40: 278. PMID 34470658 DOI: 10.1186/s13046-021-02082-7 |
0.462 |
|
| 2021 |
Song NJ, Allen C, Vilgelm AE, Riesenberg BP, Weller KP, Reynolds K, Chakravarthy KB, Kumar A, Khatiwada A, Sun Z, Ma A, Chang Y, Yusuf M, Li A, Zeng C, ... ... Liu Y, et al. Immunological Insights Into the Therapeutic Roles of CD24Fc Against Severe COVID-19. Medrxiv : the Preprint Server For Health Sciences. PMID 34462760 DOI: 10.1101/2021.08.18.21262258 |
0.477 |
|
| 2021 |
Liu Y, Nelson MV, Bailey C, Zhang P, Zheng P, Dome JS, Liu Y, Wang Y. Targeting the HIF-1α-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor. Oncogene. PMID 34155347 DOI: 10.1038/s41388-021-01907-1 |
0.592 |
|
| 2021 |
Huang X, Liu Y, Wang Y, Bailey C, Zheng P, Liu Y. Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma. Cancers. 13. PMID 33572152 DOI: 10.3390/cancers13040694 |
0.616 |
|
| 2020 |
Gao H, Cai H, Liu J, Wang X, Zheng P, Devenport M, Xu T, Dou F, Liu Y, Zhou A. Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody. Cell Discovery. 6: 79. PMID 33298884 DOI: 10.1038/s41421-020-00202-9 |
0.568 |
|
| 2020 |
Zhang P, Liu M, Cui Y, Zheng P, Liu Y. Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers. Briefings in Bioinformatics. PMID 32823273 DOI: 10.1093/bib/bbaa180 |
0.615 |
|
| 2020 |
Bailey CM, Liu Y, Peng G, Zhang H, He M, Sun D, Zheng P, Liu Y, Wang Y. Liposomal formulation of HIF-1α inhibitor Echinomycin eliminates established metastases of triple-negative breast Cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. 102278. PMID 32738299 DOI: 10.1016/J.Nano.2020.102278 |
0.59 |
|
| 2020 |
Tian RR, Zhang MX, Liu M, Fang X, Li D, Zhang L, Zheng P, Zheng YT, Liu Y. CD24Fc protects against viral pneumonia in simian immunodeficiency virus-infected Chinese rhesus monkeys. Cellular & Molecular Immunology. PMID 32382131 DOI: 10.1038/s41423-020-0452-5 |
0.524 |
|
| 2020 |
Wang Y, Liu Y, Bailey C, Zhang H, He M, Sun D, Zhang P, Parkin B, Baer MR, Zheng P, Malek SN, Liu Y. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin. Oncogene. PMID 32060420 DOI: 10.1038/S41388-020-1201-Z |
0.599 |
|
| 2020 |
Zhang P, Xiong X, Rolfo C, Du X, Zhang Y, Yang H, Russo A, Devenport M, Zhou P, Liu Y, Zheng P. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. Cancers. 12. PMID 31991588 DOI: 10.3390/Cancers12020284 |
0.644 |
|
| 2019 |
Liu Y, Zheng P. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. Trends in Pharmacological Sciences. PMID 31836191 DOI: 10.1016/j.tips.2019.11.003 |
0.657 |
|
| 2019 |
Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS. T Regulatory Cells and Priming the Suppressive Tumor Microenvironment. Frontiers in Immunology. 10: 2453. PMID 31681327 DOI: 10.3389/fimmu.2019.02453 |
0.637 |
|
| 2019 |
Zhang P, Chou HY, Young L, Zheng P, Liu Y. En masse discovery of anti-cancer human monoclonal antibodies by de novo assembly of immunoglobulin sequences from transcriptomes and genome sequences of cancer tissues. Cellular & Molecular Immunology. PMID 31562388 DOI: 10.1038/s41423-019-0299-9 |
0.577 |
|
| 2019 |
Chen C, Li F, Ma MM, Zhang S, Liu Y, Yan ZL, Chen W, Cao J, Zeng LY, Wang XY, Xu KL, Wu QY. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells. International Journal of Biological Macromolecules. PMID 31299252 DOI: 10.1016/j.ijbiomac.2019.07.065 |
0.446 |
|
| 2019 |
Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, Zheng P, Liu Y. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Research. PMID 31267017 DOI: 10.1038/s41422-019-0184-1 |
0.627 |
|
| 2019 |
Zhang P, Zheng P, Liu Y. Amplification of the Gene Is an Independent Predictor for Poor Prognosis of Breast Cancer. Frontiers in Genetics. 10: 560. PMID 31244889 DOI: 10.3389/fgene.2019.00560 |
0.589 |
|
| 2019 |
Tao R, Murad N, Xu Z, Zhang P, Okonechnikov K, Kool M, Rivero-Hinojosa S, Lazarski C, Zheng P, Liu Y, Eberhart CG, Rood BR, Packer R, Pei Y. MYC drives Group 3 medulloblastoma through transformation of Sox2+ astrocyte progenitor cells. Cancer Research. PMID 30862721 DOI: 10.1158/0008-5472.Can-18-1787 |
0.609 |
|
| 2018 |
Liu Y, Zheng P. How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity? Trends in Immunology. 39: 953-956. PMID 30497614 DOI: 10.1016/j.it.2018.10.009 |
0.623 |
|
| 2018 |
Tian RR, Zhang MX, Zhang LT, Zhang P, Ma JP, Liu M, Devenport M, Zheng P, Zhang XL, Lian XD, Ye M, Zheng HY, Pang W, Zhang GH, Zhang LG, ... Liu Y, et al. CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS. Antiviral Research. 157: 9-17. PMID 29983395 DOI: 10.1016/j.antiviral.2018.07.004 |
0.613 |
|
| 2018 |
Tang F, Du X, Liu M, Zheng P, Liu Y. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? Cell & Bioscience. 8: 30. PMID 29713453 DOI: 10.1186/s13578-018-0229-z |
0.641 |
|
| 2018 |
Zhu J, Liu JQ, Shi M, Cheng X, Ding M, Zhang JC, Davis JP, Varikuti S, Satoskar AR, Lu L, Pan X, Zheng P, Liu Y, Bai XF. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. Jci Insight. 3. PMID 29618655 DOI: 10.1172/Jci.Insight.98745 |
0.59 |
|
| 2018 |
Flores R, Zhang P, Wu W, Wang X, Ye P, Zheng P, Liu Y. Siglec genes confer resistance to systemic lupus erythematosus in humans and mice. Cellular & Molecular Immunology. PMID 29503442 DOI: 10.1038/cmi.2017.160 |
0.589 |
|
| 2018 |
Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, ... ... Liu Y, et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Research. PMID 29472691 DOI: 10.1038/s41422-018-0011-0 |
0.655 |
|
| 2018 |
Du X, Liu M, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, Zheng P. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Research. PMID 29463898 DOI: 10.1038/s41422-018-0012-z |
0.659 |
|
| 2018 |
Li D, Hu M, Liu Y, Ye P, Du P, Li CS, Cheng L, Liu P, Jiang J, Su L, Wang S, Zheng P, Liu Y. CD24-p53 axis suppresses diethylnitrosamine-induced hepatocellular carcinogenesis by sustaining intrahepatic macrophages. Cell Discovery. 4: 6. PMID 29423273 DOI: 10.1038/S41421-017-0007-9 |
0.581 |
|
| 2017 |
Tanno T, Zhang P, Lazarski CA, Liu Y, Zheng P. An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth. Blood Advances. 1: 1107-1119. PMID 29296753 DOI: 10.1182/bloodadvances.2017004705 |
0.58 |
|
| 2017 |
Tang F, Zhang P, Ye P, Lazarski CA, Wu Q, Bergin IL, Bender TP, Hall MN, Cui Y, Zhang L, Jiang T, Liu Y, Zheng P. A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. Elife. 6. PMID 29206103 DOI: 10.7554/Elife.32497 |
0.625 |
|
| 2017 |
Zhang P, Wu X, Basu M, Dong C, Zheng P, Liu Y, Sandler AD. MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database. Frontiers in Immunology. 8: 1473. PMID 29163537 DOI: 10.3389/fimmu.2017.01473 |
0.599 |
|
| 2017 |
Li N, Zheng P, Liu Y. The CD24-Siglec G axis protects mice against cuprizone-induced oligodendrocyte loss: targeting danger signal for neuroprotection. Cellular & Molecular Immunology. PMID 28757612 DOI: 10.1038/cmi.2017.47 |
0.589 |
|
| 2017 |
Toubai T, Rossi C, Oravecz-Wilson K, Zajac C, Liu C, Braun T, Fujiwara H, Wu J, Sun Y, Brabbs S, Tamaki H, Magenau J, Zheng P, Liu Y, Reddy P. Siglec-G represses DAMP-mediated effects on T cells. Jci Insight. 2. PMID 28724800 DOI: 10.1172/jci.insight.92293 |
0.507 |
|
| 2016 |
Liu Y, Wang Y, Du Z, Yan X, Zheng P, Liu Y. Fbxo30 Regulates Mammopoiesis by Targeting the Bipolar Mitotic Kinesin Eg5. Cell Reports. PMID 27117404 DOI: 10.1016/j.celrep.2016.03.083 |
0.595 |
|
| 2016 |
Li CS, Tang F, Zhang P, Jiang T, Saunders TL, Zheng P, Liu Y. Trap1a is an X-linked and cell-intrinsic regulator of thymocyte development. Cellular & Molecular Immunology. PMID 27063468 DOI: 10.1038/cmi.2015.108 |
0.633 |
|
| 2015 |
Xu X, Li L, Wang C, Liu Y, Chen C, Yan J, Ding H, Tang SY. The expansion of autologous adipose-derived stem cells in vitro for the functional reconstruction of nasal mucosal tissue. Cell & Bioscience. 5: 54. PMID 26388989 DOI: 10.1186/s13578-015-0045-7 |
0.329 |
|
| 2015 |
Li F, Li W, Liu Y, Tong YX, Zhou P, Wang L, Chen C, Zeng LY, Wu QY, Wang XY, Xu KL. Effects of the I682F mutation on JAK2's activity, structure and stability. International Journal of Biological Macromolecules. 79: 118-125. PMID 25940527 DOI: 10.1016/j.ijbiomac.2015.04.063 |
0.323 |
|
| 2015 |
Liu R, Liu C, Chen D, Yang WH, Liu X, Liu CG, Dugas CM, Tang F, Zheng P, Liu Y, Wang L. FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. Cancer Research. 75: 1703-13. PMID 25712342 DOI: 10.1158/0008-5472.CAN-14-2108 |
0.594 |
|
| 2015 |
Ye P, Liu Y, Chen C, Tang F, Wu Q, Wang X, Liu CG, Liu X, Liu R, Liu Y, Zheng P. An mTORC1-Mdm2-Drosha axis for miRNA biogenesis in response to glucose- and amino acid-deprivation. Molecular Cell. 57: 708-20. PMID 25639470 DOI: 10.1016/j.molcel.2014.12.034 |
0.64 |
|
| 2015 |
Chen Z, Shen H, Sun C, Yin L, Tang F, Zheng P, Liu Y, Brink R, Rui L. Myeloid cell TRAF3 promotes metabolic inflammation, insulin resistance, and hepatic steatosis in obesity. American Journal of Physiology. Endocrinology and Metabolism. 308: E460-9. PMID 25628422 DOI: 10.1152/ajpendo.00470.2014 |
0.569 |
|
| 2015 |
Wang L, Liu R, Ye P, Wong C, Chen GY, Zhou P, Sakabe K, Zheng X, Wu W, Zhang P, Jiang T, Bassetti MF, Jube S, Sun Y, Zhang Y, ... ... Liu Y, et al. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation. Nature Communications. 6: 5909. PMID 25600590 DOI: 10.1038/Ncomms6909 |
0.607 |
|
| 2015 |
Wong C, Chen C, Wu Q, Liu Y, Zheng P. A critical role for the regulated wnt-myc pathway in naive T cell survival. Journal of Immunology (Baltimore, Md. : 1950). 194: 158-67. PMID 25429066 DOI: 10.4049/jimmunol.1401238 |
0.677 |
|
| 2014 |
Chen GY, Brown NK, Wu W, Khedri Z, Yu H, Chen X, van de Vlekkert D, D'Azzo A, Zheng P, Liu Y. Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife. 3: e04066. PMID 25187624 DOI: 10.7554/Elife.04066 |
0.575 |
|
| 2014 |
Xiong X, Zhao Y, Tang F, Wei D, Thomas D, Wang X, Liu Y, Zheng P, Sun Y. Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis. Elife. 3: e02236. PMID 25144937 DOI: 10.7554/eLife.02236 |
0.566 |
|
| 2014 |
Chen GY, Brown NK, Zheng P, Liu Y. Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity. Glycobiology. 24: 800-6. PMID 24996822 DOI: 10.1093/glycob/cwu068 |
0.63 |
|
| 2014 |
Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G, Caligiuri MA, Zheng P, Liu Y. Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. Blood. 124: 1127-35. PMID 24994068 DOI: 10.1182/Blood-2013-12-544221 |
0.602 |
|
| 2014 |
Thaxton JE, Liu B, Zheng P, Liu Y, Li Z. Deletion of CD24 impairs development of heat shock protein gp96-driven autoimmune disease through expansion of myeloid-derived suppressor cells. Journal of Immunology (Baltimore, Md. : 1950). 192: 5679-86. PMID 24808359 DOI: 10.4049/jimmunol.1302755 |
0.628 |
|
| 2014 |
Toubai T, Hou G, Mathewson N, Liu C, Wang Y, Oravecz-Wilson K, Cummings E, Rossi C, Evers R, Sun Y, Wu J, Choi SW, Fang D, Zheng P, Liu Y, et al. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 123: 3512-23. PMID 24695850 DOI: 10.1182/blood-2013-12-545335 |
0.62 |
|
| Show low-probability matches. |